At Metabolomics Australia (MA) we combine high-throughput analytical technologies for the detection and quantification of metabolites in biological systems with the application of bioinformatics tools for data analysis, mining and interpretation.

We conduct targeted and/or non-targeted studies of small molecules (metabolites). The resulting profiles can reflect the actual cellular condition and provide useful indicators (biomarkers) of abnormalities/health within the biological system. Metabolomics requires robust experimental design with reliable sampling to capture the steady state levels of thousands of metabolites. We use complementary analytical and informatics platforms to detect the response of metabolites to environmental and genetic stimuli.

While we are a fee-for-service facility, we operate in a collaborative manner and work with you around your biological question. With our expertise in metabolomics and your knowledge of the biology we work on the best strategy for development of a research plan.

The Cancer Single Cell Genomics Laboratory (CSCG) specialises in using innovative single cell techniques to deconstruct tissue samples and reveal the genetic architecture of individual cells and offers training, advice on experimental design and collaboration options. 

The ONJ Cancer Centre is also home to the ACRF Centre for Imaging the Tumour Environment (CITE) which can provide researchers with the information required for the development of effective anti-cancer therapies. CITE offers one-on-one customised training, advice on experimental design and collaboration options. Researchers are supported at all stages of their project from design through to image analysis and reporting.

The Melbourne Mass Spectrometry and Proteomics Facility (MMSPF) located at the Bio21 Institute is one of the largest mass spectrometry facilities in Australia. The MMSPF is an open access facility that provides academic and industry researchers access to specialist mass spectrometry and proteomic equipment and expertise.  

The Facility has 15 mass spectrometer based systems and five full time Ph.D. staff dedicated to providing all experimental design, training, machine time, and informatics support required to execute any proteomics or lipidomics research project.  The facility provides all users direct access to instrumentation and trains them to perform their own proteomics or lipidomics experiments. 

Techniques such as protein identification (e.g. Gel spots, or immuno-precipitated protein), full scale proteomics (TMT, SILAC, DIA, Label free, etc), phosphoproteomics , N-Terminomics (in-vivo protease activity), protein structural characterisation (PTM's, disulphide arrangement, HDX, Crosslinking).   

The facility has the following instrumentation:
• 2 x Thermo OrbiTrap Fusion Lumos
• 2 x Thermo Q Exactive Plus Mass spectrometer
• 2 x Thermo OrbiTrap Eclipse mass spectrometer
• Thermo OrbiTrap Exploris 480
• Thermo OrbiTrap Exactive plus
• Agilent 6520 LC/ESI-TOF mass spectrometer
• Waters XS IMS QTOF Mass spectrometer
• Waters HDX Synapt system
• Bruker TIMS TOF Pro
• Shimadzu  9030 QTOF
• Shimadzu 8050 QQQ

AGRF is a not-for-profit organisation, committed to quality and innovation.  We actively seek to partner and share our knowledge and expertise in genomics. Through our national network, AGRF provides access to innovative and leading technologies, enabling genomics in the biomedical, agricultural and environmental sectors. From single gene analysis to whole genome sequencing (WGS), AGRF provides a full range of genomic capabilities and services with complementary bioinformatics across the entire biological spectrum, to academia, healthcare and commercial industries.

SVI focus on a wide range of disease-oriented research: 

Our in-house tools include: 

MPMP perform targeted and untargeted proteomics, lipidomics and metabolomics studies for a wide range of biomedical and pharmaceutical applications.

The Molecular Genomics Core at Peter Mac processes samples, implements and develops new genomics protocols for cancer research and translational applications. We work predominantly with Next Generation Sequencing (NGS, Illumina compatible) but also with the nCounter technology (Nanostring) for gene expression of FFPE-derived samples. We operate a Chromium iX for single-cell sequencing and the Visium (10xGenomics) and GeoMx DSP (Nanostring) for spatial transcriptomics. We specialize in custom protocols and challenging cancer samples such as low input and FFPE-derived. 

The VCGS/MCRI Genomics Facility offers a diverse portfolio of sequencing services on a clinical and research basis. We offer DNA and RNA extraction, Next Generation Sequencing assays (including sample QCs, library preparation, library QC, and sequencing; but currently excluding bioinformatics). The laboratory is NATA accredited and operates in accordance with NPAAC and ISO15189 standards.

The VCFG is a high throughput screening facility that enables researchers Australia-wide the opportunity to become fully trained to perform screens across CRISPR, RNAi and Compound platforms. The lab has an extensive array of reagent libraries, automated liquid handling, plate reader and imaging instrumentation. Projects can be performed in 2D and 3D settings, with cell lines or patient derived materials. Every project is customised and analysed in house and managed using PRIME, our PRoject Information and Management Enterprise. 

The Proteomics Facility at WEHI enables researchers and clinicians to utilise the advanced proteomic technologies available at WEHI. We employ five full-time, post-doctoral researchers and have seven mass spectrometers for analysis of proteomics samples. We charge users the hours spent by facility staff on preparation of samples, instrument time (data acquisition on the mass spectrometer) and data analysis.

The University of Melbourne Centre for Cancer Research (UMCCR) brings together university leaders committed to improving the outcomes and quality of life for people affected by cancer. Led by Professor Sean Grimmond, an international leader in cancer genomics, the UMCCR takes a personalised, patient-centric approach, targeting key points along the cancer clinical care pathway.

Comprehensive genomics facility for internal and precinct researchers offering Illumina, MGI and Nanopore sequencing options and focusing on functional, single-cell and spatial genomics. Interests in high-throughput transcriptomics, pathogen genomics, functional genomics assays, improvements to existing assays and clinical or cohort-based studies. Expertise in overhang amplicon and CRISPR sequencing. Collaborative methods development and advanced genomics projects undertaken, sequencing as a service, experimental design and bioinformatics offered.